PubMed Health⌕ Search

PubMed · 9559255

Heart rate variability.

Abstract

Heart rate variability is a recognized tool for the estimation of cardiac autonomic modulations. Recently, several studies have advanced the field of heart rate variability in three areas: 1) in technical modes of electrocardiogram processing and heart rate variability assessment, 2) in physiologic understanding and interpretation, and 3) in clinical and practical use. The most recent technical studies concentrate on the analysis of nonlinear aspects of heart period variations and on coherence between electrocardiogram variability and other physiologic factors such as respiration. Principal physiologic investigations studied the components of heart rate variability attributable to the individual limbs of the autonomic nervous system. It is becoming recognized that behavior and responses to the environment, including the psychosocial environment, play an important role in long-term heart rate variability. Established clinical applications of heart rate variability are presently restricted to the assessment of risk after myocardial infarction and to the early diagnosis of diabetic neuropathy. Nevertheless, recent studies indicate that heart rate variability might soon become a similarly powerful tool for risk prediction and monitoring of disease progression in congestive heart failure and for monitoring or reinnervation after heart transplantation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Malik. 1998. Heart rate variability.. https://doi.org/10.1097/00001573-199801000-00006

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Neurological phenotype in Waardenburg syndrome type 4 correlates with novel SOX10 truncating mutations and expression in developing brain.

Waardenburg syndrome type 4 (WS4), also called Shah-Waardenburg syndrome, is a rare neurocristopathy that results from the absence of melanocytes and intrinsic ganglion cells of the terminal hindgut. WS4 is inherited as an autosomal recessive trait attributable to EDN3 or EDNRB mutations. It is inherited as an autosomal dominant condition when SOX10 mutations are involved. We report on three unrelated WS4 patients with growth retardation and an as-yet-unreported neurological phenotype with impairment of both the central and autonomous nervous systems and occasionally neonatal hypotonia and arthrogryposis. Each of the three patients was heterozygous for a SOX10 truncating mutation (Y313X in two patients and S251X [corrected] in one patient). The extended spectrum of the WS4 phenotype is relevant to the brain expression of SOX10 during human embryonic and fetal development. Indeed, the expression of SOX10 in human embryo was not restricted to neural-crest-derived cells but also involved fetal brain cells, most likely of glial origin. These data emphasize the important role of SOX10 in early development of both neural-crest-derived tissues, namely melanocytes, autonomic and enteric nervous systems, and glial cells of the central nervous system.

Autonomic Nervous System↗

Effect of mibefradil on heart rate variability in patients with chronic heart failure.

BACKGROUND: Mibefradil was recently withdrawn from the market because of an unfavorable clinical profile in patients with chronic heart failure. Although drug interactions appear to play a role, other mechanisms such as proarrhythmia and autonomic deterioration could also be relevant. Chronic heart failure is accompanied by autonomic impairment and analysis of heart rate variability can be used to examine autonomic modulation of heart rate. METHODS: We studied 18 heart failure patients (age 63.2+/-10.1 years (mean+/-S.D. ), ejection fraction 0.21+/-0.07) treated with mibefradil or placebo, who participated in the MACH-I (Mortality Assessment in Chronic Heart failure) trial in our center, and compared them with 18 healthy matched controls. Heart rate variability analysis was performed at baseline and after 7 months of treatment. RESULTS: At baseline, heart rate variability parameters were impaired in patients with heart failure compared to healthy controls (P<0.05). After 7 months of treatment a reduction in (24-h) heart rate was observed (P=0.02, versus placebo). Apart from the effect on mean NN, no significant differences were observed for the remaining heart rate variability parameters. CONCLUSIONS: Mibefradil does not impair autonomic balance and in fact reduces heart rate in patients with heart failure. These findings suggest that autonomic activation did not contribute to the adverse effects of mibefradil.

Autonomic Nervous System↗